We keep you informed of MPN-related Clinical Trial Updates and News:
Get the latest news on MPN research, clinical trials, treatments, education, and advocacy.
- CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib (4/25/15)
- CRISPR Researchers Target Incurable Blood Cancer
- Pacritinib demonstrates safety, efficacy for patients with myelofibrosis
- The Fleischman Lab Continues Investigating the Role of Inflammation in MPN
- New study for patients with myeloproliferative neoplasms (MPN)
- Increased incidence of another cancer in MPN patients
Patient & Caregiver Support
Join with other patients to learn more about your disease and treatment options through an in-person or online support group. Many major cities throughout the United States and internationally host regular meetings. Contact Ann Brazeau if you are interested in establishing a new Support Group for your area : 517.899.6889 firstname.lastname@example.org
Science Advisor: Ruben Mesa
Dr. Mesa was one of the featured speakers at the Washington D.C. Patient Education Symposium held in March 2015.
Read his latest update: MPN Highlights from the American Society of Hematology
Free Patient Info Pack
Give us your address and we’ll send you a free informational package in the mail. Your contact information will be kept strictly confidential. Sign Up Now
What is a myeloproliferative neoplasm? MPNs are a group of rare blood cancers that overproduce blood cells in the bone marrow, and are caused by genetic mutations in the blood stem cells:
- Myelofibrosis is a rare bone marrow cancer. Bone marrow cells that produce blood cells develop and function abnormally resulting in fibrous scar tissue formation.
- Polycythemia Vera is a disorder in which the bone marrow makes too many red blood cells. It may also result in the production of too many other types of blood cells – white blood cells and platelets.
- Essential Thrombocythemia causes the body to produce too many blood platelets-thrombocytes. It can cause abnormal clotting or bleeding. The bone marrow makes too many platelet-forming cells or megakaryocytes, which release platelets into your blood.